Recent events
Recent events tied to this brand in public sources.
Back to profile51 entries · Page 3 of 3
2020
Novartis completes acquisition of The Medicines Company
Novartis announced that it completed its acquisition of The Medicines Company through a merger; The Medicines Company became an indirect wholly-owned subsidiary of Novartis.
2019
Voluntis and Novartis announce oncology collaboration
Voluntis announced a collaboration with Novartis to evaluate the use of Voluntis' digital therapeutic platform for breast cancer patients. The digital therapeutic will be evaluated in an upcoming prospective clinical trial.
2019
AWS and Novartis enter strategic collaboration
Amazon Web Services entered into a multi-year strategic collaboration with Novartis to use AWS cloud services in Novartis's pharmaceutical manufacturing, supply chain and delivery operations.
2019
Eris Lifesciences acquires Zomelis trademarks for India
Eris Lifesciences said it acquired the Zomelis trademark and associated trademarks from Novartis AG for the Indian market for USD 13 million.
2019
Drugmakers agree to reduce prices of some medicines in China
Chinese regulators said pharmaceutical companies, including Roche and Novartis, agreed to reduce the China prices of some newer medicines by an average of 61% to enter the national medical insurance reimbursement list.
2019
Novartis announces agreement to acquire The Medicines Company
The Medicines Company announced a definitive agreement under which Novartis would acquire it in an all-cash transaction valued at approximately $9.7 billion on a fully diluted basis. The acquisition had not yet been completed.
2019
FDA approves Adakveo for sickle cell disease pain crises
The FDA approved crizanlizumab (Adakveo, Novartis) to reduce the frequency of pain crises among people with sickle cell disease; the article states it is indicated for patients aged 16 or older.
2019
Tencent and Novartis launch AI heart-failure management platform
Tencent and Novartis launched “护心小爱(AI),” an AI-based disease-management platform for heart-failure patients, during the China International Import Expo. The platform uses a WeChat mini program to provide services including health-indicator recording, answers to everyday questions, medication reminders and heart-failure information.
2019
Novartis and Fiocruz sign memorandum of understanding on neglected diseases
Novartis signed a memorandum of understanding with Brazil’s Oswaldo Cruz Foundation (Fiocruz) to formalize cooperation intentions in teaching, research and technological development projects addressing neglected diseases.
2019
Eyevance acquires Tobradex ST and Natacyn
Eyevance Pharmaceuticals acquired Tobradex ST and Natacyn from Novartis. Financial details were not released.
2019
Eyevance acquires TOBRADEX ST and NATACYN
Eyevance Pharmaceuticals announced that it acquired TOBRADEX ST and NATACYN from Novartis. The source also says Eyevance acquired global rights to NATACYN.